Showing 5091-5100 of 5644 results for "".
- SEED Acquires Majority Stake in Sensimedhttps://modernod.com/news/seed-acquires-majority-stake-in-sensimed/2477166/Sensimed announced the closure of a transaction whereby the Japanese public company SEED has acquired a majority stake in Sensimed. The transaction closed on November 29 with SEED now owning over 90% of outstanding sh
- Staar Surgical Announces FDA IDE Clinical Study Approvalhttps://modernod.com/news/staar-surgical-announces-fda-ide-clinical-study-approval-2/2477164/Staar Surgical announced that the FDA, in a letter dated December 6, 2019, stated that it has determined that Staar has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ VISIAN Implantable Collamer Lens for Myopia, and EVO/EVO+ VISIAN To
- Genentech/Roche’s Faricimab Phase 3 Program Fully Recruited with Enrollment Completion of Wet AMD Clinical Trialshttps://modernod.com/news/genentech-roches-faricimab-phase-3-program-fully-recruited-with-enrollment-completion-of-wet-amd-clinical-trials/2477161/Genentech and Roche have completed patient enrollment in the TENAYA and LUCERNE phase 3 clinical trials investigating faricimab for the treatment of wet age-related macular degeneration (AMD). The phase 3 YOSEMITE and RHINE diabetic macular edema (DME) clinical trials completed patient enrollment
- Bausch + Lomb Introduces Envista Toric MX60ET IOL With Stableflex Technologyhttps://modernod.com/news/bausch-lomb-introduces-envista-toric-mx60et-iol-with-stableflex-technology/2477160/Bausch + Lomb has introduced the enVista toric MX60ET hydrophobic acrylic IOL with StableFlex technology. Bausch + Lomb says the MX60ET provides improved material properties to deliver enhanced optic recovery following delivery. Like the enVista toric MX60T, the MX60ET offers a glistening free op
- Tom Frinzi to Retire; Warren Foust Appointed President of J&J Vision Surgicalhttps://modernod.com/news/tom-frinzi-to-retire-from-johnson-replaced-by-warren-foust/2477156/Johnson & Johnson Vision announced that Warren Foust will assume the role of Worldwide President, Surgical for Johnson & Johnson Vision, effective December 2. Mr. Foust replaces Tom Frinzi, who will retire at the end of 2019 after a 35-year career in ophthalmology. Mr. Frinzi was
- AI Diagnostics Company IDx Announces New Appointments to its Executive Leadership Teamhttps://modernod.com/news/ai-diagnostics-company-idx-announces-new-appointments-to-its-executive-leadership-team/2477153/IDx Technologies announced several new appointments to its executive leadership team to accelerate product development and scale operations to accommodate increased market adoption of IDx-DR, according to a company news release. IDx-DR is an FDA-authorized autonomous AI system that detects diabet
- AAO and ASCRS Launch “Ophthovation” Joint Venture Business Innovation Conferenceshttps://modernod.com/news/aao-and-ascrs-launch-ophthovation-joint-venture-business-innovation-conferences/2477151/Two of the world’s largest ophthalmic organizations have finalized their joint venture “Ophthovation” to develop business conferences that accelerate innovation in ophthalmology. Called the Ophthovation Conference, the meeting will be held every year prior to the annual meetings of th
- Sight Sciences Appoints Erica Rogers to its Board of Directorshttps://modernod.com/news/sight-sciences-appoints-erica-rogers-to-its-board-of-directors/2477149/Sight Sciences announced the appointment of Erica Rogers to the company’s board of directors. Ms. Rogers, President and CEO of Silk Road Medical, is an experienced leader and entrepreneur in the medical device industry. She most recently led Silk Road Medical through FDA approval of
- Nicox Signs Agreement for Zerviate in South Koreahttps://modernod.com/news/nicox-signs-agreement-for-zerviate-in-south-korea/2477143/Nicox announced the signature of an exclusive license agreement with Samil Pharmaceutical for the development and commercialization of Zerviate (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in South Korea. Samil Pharmaceutical i
- Aldeyra Therapeutics Announces Topline Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-part-1-of-adaptive-phase-3-renew-trial-in-dry-eye-disease/2477138/Aldeyra Therapeutics announced positive topline results from Part 1 of the adaptive phase 3 RENEW trial of topical ocular reproxalap in patients with dry eye disease, according to a company news release. “To our knowledge, reproxalap is the first topical dry eye disease drug to demonstrate